Status:
UNKNOWN
SAfety and EFficacy of Bridging Antithrombotic Therapy During Elective Non-cardiac Surgery
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Brief Summary
Patients with coronary artery disease, especially after PCI, require long-term oral antiplatelet therapy. However, this patient population may inevitably require non-cardiac surgery for a variety of c...
Eligibility Criteria
Inclusion
- Aged 18 years or over
- Established coronary artery disease being treated with oral antiplatelet therapy
- Non-cardiac surgery is planned and bridging antithrombotic therapy is considered necessary
- Agree to participate in the study and provide written informed consent
Exclusion
- According to the consensus of Chinese experts on antiplatelet therapy in 2013, the surgical bleeding risk is low or extremely low
- Requiring emergency non-cardiac surgery within 24 hours after admission
- Currently being bleeding
- Moderate or severe ischemic stroke or spontaneous intracranial hemorrhage in the past 6 months or traumatic intracranial hemorrhage in the past 1 year
- Intracranial diseases or hemorrhagic diathesis
- Contraindications for LMWH or GP IIb/IIIa receptor antagonists
Key Trial Info
Start Date :
March 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
950 Patients enrolled
Trial Details
Trial ID
NCT04675801
Start Date
March 2 2021
End Date
June 1 2023
Last Update
November 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100029